2024-511934-11-00SuspendedPhase 2
A randomized, open-label, multi-arm, two-part, phase II study to assess the efficacy and safety of multiple LXH254 combinations in patients with previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Suspended
- Sponsor
- Novartis Pharma AG
- Enrollment
- 53
- Locations
- 11
- Primary Endpoint
- Confirmed ORR using RECIST v1.1, per local assessment
Study Overview
Brief Summary
To evaluate the efficacy of each combination arm based on Objective Response Rate (ORR) as confirmed by RECIST 1.1, per local assessments
Eligibility Criteria
- Ages
- 0 years to 65+ years (18-64 Years, 65+ Years, 0-17 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Male or female must be ≥ 12 years
- •For adolescent participants only (12-17 years): body weight > 40kg
- •Histologically confirmed unresectable or metastatic cutaneous melanoma
- •Documentation of BRAFV600 or NRAS mutation in tumor tissue prior to study treatment as determined by local assay or as determined by central pre-screening assessment performed at a Novartis designated laboratory
- •Previously treated for unresectable or metastatic melanoma: Participants with NRAS mutation: Participants must have received prior systemic therapy for unresectable or metastatic melanoma with checkpoint inhibitors (CPI), either an anti-PD-1/PD-L1 as a single agent or in combination with anti-CTLA-4, investigational agents, chemotherapy or locally directed anti-neoplastic agents Prior checkpoint inhibitor therapy in the unresectable or metastatic setting is not required for participants who have progressed on or within 6 months of adjuvant therapy with a checkpoint inhibitor Prior therapy with T-VEC (talimogene laherparepvec) is allowed and will not be counted as a prior line of systematic therapy A maximum of two prior lines of systemic CPI-containing immunotherapy for unresectable or metastatic melanoma are allowed. Additional agents administered with a CPI are permitted. To rule out pseudo-progression, participants must have documented confirmed progressive disease as per iRECIST v1.1 while on/after treatment with checkpoint inhibitor therapy. Confirmation is not required for patients who remained on treatment >6 months Participants with BRAFV600 mutant disease: Participants must have received prior systemic therapy for unresectable or metastatic melanoma with a checkpoint inhibitor (CPI), either an anti-PD-1/ anti-PD-L1 as a single agent or in combination with anti-CTLA-4, investigational agents, chemotherapy or locally directed anti-neoplastic agents. Additionally, participants must have received targeted therapy with a RAFi as a single agent or in combination with a MEKi (+/- CPI allowed) as the last prior therapy Prior checkpoint inhibitor therapy in the unresectable or metastatic setting is not required for participants who have progressed on or within 6 months of adjuvant checkpoint inhibitors Prior therapy with T-VEC (talimogene laherparepvec) is allowed and will not be counted as a prior line of systemic therapy A maximum of two prior lines of CPI-containing systemic immunotherapy for unresectable or metastatic melanoma are allowed. Additional agents with CPI are permitted A maximum of one line of targeted therapy is allowed, and it must be the most recent line of therapy If a participant discontinued targeted therapy for reasons other than disease progression, a switch to another targeted therapy regimen is allowed Participants must have documented progressive disease as per RECIST v1.1 while on/after treatment with targeted therapy
- •Participants must have a site of disease amenable to repeated biopsies and must be willing to undergo a new tumor biopsy at baseline and during treatment according to the treating institution’s own guidelines and requirements for such procedures. For screening biopsy, exceptions may be made for patients who have recently undergone a fresh tumor biopsy out of the screening window and have received no intervening therapy, after discussion with the Novartis medical monitor. Bone metastases are not acceptable as a site for biopsy
Exclusion Criteria
- •All primary central nervous system (CNS) tumors or symptomatic CNS metastases that are neurologically unstable
- •Insufficient bone marrow, hepatic or renal function at the screening visit
- •Abnormal ECG as determined by the mean of a triplicate ECG and assessed locally
- •Cardiac disease or cardiac repolarization abnormality
- •Presence of ≥ CTCAE grade 2 toxicity (except alopecia) due to prior anti-cancer therapy. Grade 2 endocrinopathies being treated with replacement therapy and that are no longer symptomatic
- •History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes)
Outcomes
Primary Outcomes
Confirmed ORR using RECIST v1.1, per local assessment
Confirmed ORR using RECIST v1.1, per local assessment
Secondary Outcomes
- Serum/plasma concentration and pharmacokinetic parameters of each combination regimen
- Safety: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) including changes in laboratory values, vital signs and cardiac assessment
- Tolerability: Dose interruptions, reductions, and permanent discontinuations of study treatments
- DoR, PFS and DCR using RECIST v1.1, per local assessment
- DoR, PFS, DCR and ORR, assessed using RECIST v1.1, per central assessment for all participants (selection and expansion) for the combination arms that moved to expansion
- Overall survival (OS)
Investigators
Novartis Pharma Arzneimittel GmbH
Scientific
Novartis Pharma AG
Study Sites (11)
Loading locations...
Similar Trials
Completed
Phase 2
Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal CancerColorectal CancerNCT00202787Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)136
Terminated
Phase 2
Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.Metastatic Colorectal CancerNCT00531115Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)28
Completed
Phase 2
Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaMelanomaNCT00289640Bristol-Myers Squibb210
Completed
Phase 2
Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab MonotherapyParoxysmal Nocturnal HemoglobinuriaNCT04811716Regeneron Pharmaceuticals24
Terminated
Phase 2
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)Recurrent Glioblastoma Multiforme (GBM)NCT00290771Novartis231